VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res. 2011 Jul; 31(7):2461-5.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Bacterial Proteins
Bevacizumab
Cell Line, Tumor
Diphtheria Toxin
Female
Growth Inhibitors
Heparin-binding EGF-like Growth Factor
Humans
Intercellular Signaling Peptides and Proteins
Mice
Mice, Inbred BALB C
Mice, Nude
Neovascularization, Pathologic
Ovarian Neoplasms
Paclitaxel
Protein Kinase Inhibitors
Xenograft Model Antitumor Assays
authors with profiles
YOKO TAKAHASHI